Items where authors include "Ojo, O."

Article

Abani, O., Abbas, A., Abbas, F. et al. (7724 more authors) (2025) Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Abani, O., Abbas, A., Abbas, F. et al. (8041 more authors) (2025) Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Infectious Diseases. ISSN 1473-3099

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. EClinicalMedicine, 81. 103080. ISSN 2589-5370

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Adisa, A., Bahrami-Hessari, M., Bhangu, A. orcid.org/0000-0001-5999-4618 et al. (2460 more authors) (2023) Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries. British Journal of Surgery, 110 (7). pp. 804-817. ISSN 0007-1323

Adisa, A., Bahrami-Hessari, M., Bhangu, A. et al. (1891 more authors) (2023) Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries. British Journal of Surgery, 110 (7). pp. 804-817. ISSN 0007-1323

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Proceedings Paper

Walls, G., Horne, A., Harrow, S. et al. (17 more authors) (2025) 3513: ATM inhibition with AZD1390 and conventional radiotherapy in non-small cell lung cancer: interim report from the CONCORDE phase Ib trial (NCT04550104). In: Radiotherapy and Oncology. ESTRO 2025, 02-06 May 2025, Vienna, Austria. , s1395-s1397.

Horne, A., Walls, G., Brown, S. et al. (17 more authors) (2025) An update on the CONCORDE study: a phase Ib platform study of DNA damage repair inhibitors (DDRIs) in combination with conventional radiotherapy in NSCLC. In: Journal of Thoracic Oncology. European Lung Cancer Congress 2025, 26-29 Mar 2025, Paris, France. Elsevier BV , S150.

Walls, G., Horne, A., Franks, K. et al. (23 more authors) (2025) 255 An update on the CONCORDE study: a phase Ib platform study of DNA damage repair inhibitors (DDRis) in combination with conventional radiotherapy in NSCLC. In: Lung Cancer. 23rd BTOG Annual Conference 2025, 03-05 Mar 2025, Belfast, Northern Ireland. Elsevier BV , p. 108364.

Greystoke, A., Oughton, J.B., Brown, S.R. et al. (16 more authors) (2024) Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC). In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. ASCO Publications .